Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIMODE: CS1 in Pulmonary Arterial Hypertension
NCT07761572Phase 2Not yet recruiting
- Sponsor
- Cereno Scientific AB
- Start
- Sep 2026
- Primary completion
- Feb 2029
01
Overview
A Phase 2 trial of bisantrene in pulmonary arterial hypertension (PAH), sponsored by Cereno Scientific AB. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bisantrene
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07761572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07761572.